Pre-earnings options volume in Theravance Biopharma (TBPH) is normal with puts leading calls 5:3. Implied volatility suggests the market is anticipating a move near 3.2%, or 0c, after results are released. Median move over the past eight quarters is 6.4%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
- Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
- Theravance Biopharma price target lowered to $15 from $27 at H.C. Wainwright
- Theravance Biopharma downgraded to Neutral from Buy at B. Riley
- Theravance Biopharma price target lowered to $21 from $40 at BTIG